天津医药

• 临床论丛 •    

不同剂量白介素-2在局部进展性肾癌术后免疫治疗中的疗效评价

王希路1,胡海龙2,吴长利3   

  1. 1. 天津市大港医院外三科
    2. 天津医科大学第二医院泌尿外科
    3. 医大二院泌尿外科
  • 收稿日期:2010-01-11 修回日期:2010-05-22 出版日期:2010-09-15 发布日期:2010-09-15
  • 通讯作者: 王希路

Therapeutic effect evaluation of different dose interleukin-2 in immunotherapy of locally advanced renal cell carcinoma after radical nephrectomy

  • Received:2010-01-11 Revised:2010-05-22 Published:2010-09-15 Online:2010-09-15

PDF (PC)

2664

摘要： 摘要 目的：评价低剂量重组白介素-2（IL-2）在局部进展性肾癌患者肾根治性切除术后的疗效及副作用。方法：2003年3月-2006年3月，行肾癌根治性切除术后经病理诊断为Ⅲ期肾癌患者38例，患者分为3组，分别予中等剂量18 MIU/M2（A组），低剂量1MIU/M2（B组）及0.5 MIU/M2（C组）IL-2进行皮下注射治疗，其中A组患者8例，B组患者14例，C组患者16例。治疗期间，间隔3个月复查彩超及胸部正位片以明确转移及局部复发情况。应用NCI CTC 3.0评估毒性反应。所有患者随访14-40个月。结果：3组患者最终全部完成治疗者分别为5例（62.5%）、11例（78.57%）及16例（100%），3组患者在随诊期间肿瘤复发率、肿瘤远处转移率及死亡率均无明显差异（P＞0.05）。与A组比较，B组及C组患者药物副作用发生几率显著下降（P＜0.05）。结论：低剂量IL-2治疗RCC的客观疗效与常规临床应用剂量比较疗效相同，毒副反应轻,患者可耐受，低危患者有可能明显获益。

关键词: 白介素-2, 肾癌, 免疫治疗

Abstract: Abstract Objective: To evaluate the efficacy and safety of a regimen of low-dose interleukin-2 (IL-2) in the treatment for patients with locally advanced renal cell carcinoma (LA-RCC). Methods: We retrospectively analyses the records of all 38 patients who underwent radical nephrectomy which have been certified LA-RCC in our hospital from March 2003 to March 2006. Patients be sub grouped to three groups and group A, B and C received 18 MIU/M2, 1MIU/M2 and 0.5 MIU/M2 IL-2 subcutaneously QOD. Every three month all patients were examination by ultrasound, chest roentgenograms. Groups were compared using Student's t-test, and a probability (P) value of less than 0.05 was taken to indicate statistical significance. Results: 5，11 and 16 patients of group A,B and C complete the treatment at last. There was no significiantly difference among the three groups in the rate of tumor recurrence, tumor metastasis and death (P＞0.05). the side effect of IL-2 in group B and C was significiantly less than group A (P＜0.05). Conclusion: Adminstered low-dose IL-2 may be a safe and effective option to LA-RCC, especially for low-risk LA-RCC patients. Key words: Interleukin-2, Renal cell carcinoma, Immunotherapy

Key words: Interleukin-2, Renal cell carcinoma, Immunotherapy